EV Biologics Corp, announced that it has closed a $500,000 interest-free loan from a related party. This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process. The funds will be also used for comprehensive product analysis by several leading independent laboratories.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6221 USD | +3.32% | +3.32% | -37.79% |
2023 | EV Biologics, Inc. Closes A $500,000 Interest-Free Loan | CI |
2023 | Ev Biologics Completes Production of Cutting-Edge Msc Exosome-Based Therapeutic | CI |
1st Jan change | Capi. | |
---|---|---|
-37.79% | 6.36M | |
+20.60% | 48.58B | |
-3.74% | 15.52B | |
+3.55% | 15.46B | |
-15.73% | 10.44B | |
+26.55% | 8.84B | |
+105.28% | 8.27B | |
-0.30% | 7.96B | |
-8.75% | 7.34B | |
+23.97% | 6.73B |
- Stock Market
- Equities
- YECO Stock
- News EV Biologics, Inc.
- EV Biologics, Inc. Closes A $500,000 Interest-Free Loan